Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NCI Drug Dictionary

Please enter up to 30 characters for your search

29 results found for: J

Jadenu
(Other name for: deferasirox)
JAK inhibitor
Any agent that targets, binds to and inhibits the activity of one or more of the Janus kinase family of enzymes.
JAK inhibitor INCB047986
An orally bioavailable inhibitor of Janus-associated kinases (JAK), with potential antineoplastic activity. Upon oral administration, INCB047986 specifically binds to and inhibits the phosphorylation of JAK, which affects JAK-dependent signaling and may lead to an inhibition of cellular proliferation in JAK-overexpressing tumor cells. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.
JAK1 inhibitor INCB052793
An orally bioavailable inhibitor of Janus-associated kinase 1 (JAK1), with potential antineoplastic activity. Upon oral administration, INCB052793 specifically binds to and inhibits the phosphorylation of JAK1, which interferes with JAK-dependent signaling and may lead to an inhibition of cellular proliferation in JAK1-overexpressing tumor cells. The JAK-STAT (signal transducer and activator of transcription) signaling pathway is a major mediator of cytokine activity and is often dysregulated in a variety of tumor cell types.
JAK2 inhibitor AZD1480
An orally bioavailable inhibitor of Janus-associated kinase 2 (JAK2) with potential antineoplastic activity. JAK2 inhibitor AZD1480 inhibits JAK2 activation, leading to the inhibition of the JAK/STAT (signal transducer and activator of transcription) signaling including activation of STAT3. This may lead to induction of tumor cell apoptosis and a decrease in cellular proliferation. JAK2, often upregulated or mutated in a variety of cancer cells, mediates STAT3 activation and plays a key role in tumor cell proliferation and survival.
JAK2 inhibitor BMS-911543
An orally available small molecule targeting a subset of Janus-associated kinase (JAK) with potential antineoplastic activity. JAK2 inhibitor BMS-911543 selectively inhibits JAK2, thereby preventing the JAK/STAT (signal transducer and activator of transcription) signaling cascade, including activation of STAT3. This may lead to an induction of tumor cell apoptosis and a decrease in cellular proliferation. JAK2, often upregulated or mutated in a variety of cancer cells, mediates STAT3 activation and plays a key role in tumor cell proliferation and survival.
JAK2 inhibitor BS HH 002.SA
A derivative of the cytotoxic plant alkaloid homoharringtonine (HHT) and an inhibitor of Janus-associated kinase 2 (JAK2), with potential antineoplastic activity. Upon administration, JAK2 inhibitor BS HH 002.SA inhibits JAK2 activity, thereby preventing the activation of the JAK/signal transducer and activator of transcription (STAT) signaling pathway and the activation of STAT3 and STAT5. This may lead to an induction of tumor cell apoptosis and a decrease in tumor cell proliferation. JAK2, often upregulated or mutated in a variety of cancer cells, mediates STAT3 activation and plays a key role in tumor cell proliferation and survival.
JAK2 inhibitor TQ05105
An orally bioavailable inhibitor of Janus-associated kinase 2 (JAK2), with potential antineoplastic activity. Upon oral administration, JAK2 inhibitor TQ05105 inhibits JAK2 activity, thereby preventing the activation of the JAK/STAT (signal transducer and activator of transcription) signaling pathway and the activation of STAT3. This may lead to an induction of tumor cell apoptosis and a decrease in tumor cell proliferation. JAK2, often upregulated or mutated in a variety of cancer cells, mediates STAT3 activation and plays a key role in tumor cell proliferation and survival.
JAK2 inhibitor XL019
An orally bioavailable inhibitor of Janus-associated kinase 2 (JAK2) with potential antineoplastic activity. XL019 inhibits the activation of JAK2 as well as the mutated form JAK2V617F, which may result in the inhibition of the JAK-STAT signaling pathway and may induce apoptosis. The JAK2 mutated form JAK2V617F has a valine-to-phenylalanine modification at position 617 and plays a key role in tumor cell proliferation and survival.
Jakafi
(Other name for: ruxolitinib phosphate)
Jardiance
(Other name for: empagliflozin)
Jarlsberg cheese
An orally bioavailable nutritional supplement composed of vitamin K2-rich cheese that can be used to increase levels of osteocalcin and vitamin K, and may have bone protective, lipid regulating and blood pressure modulating activities. Upon oral administration, the vitamin K2-rich cheese may be able to increase the ratio of carboxylated to undercarboxylated osteocalcin and increase the levels of long-chained vitamin K2. In addition, the cheese supplement may reduce total cholesterol, low-density lipoprotein (LDL)-cholesterol, and the LDL/high-density lipoprotein (HDL) ratio. It may also positively affect blood pressure.
Jaypirca
(Other name for: pirtobrutinib)
JEB regimen
A regimen consisting of bleomycin, etoposide and carboplatin used to treat advanced-stage ovarian and testicular germ-cell tumors in children.
Jelmyto
(Other name for: mitomycin)
Jemperli
(Other name for: dostarlimab-gxly)
Jevtana
(Other name for: cabazitaxel)
Jianpi Huatan decoction
A traditional Chinese medicine (TCM) decoction that may be used for the treatment of advanced colorectal cancer.
Jianpi Qushi Huatan decoction
A traditional Chinese medicine (TCM) containing, among other ingredients, Radix astragali, Atractylodes Lancea, Dioscorea oppositifolia, Cyperus rotundus, Lindera aggregata, Aconitum gymnandrum and Ligusticum wallichii. Upon oral administration of Jianpi Qushi Huatan decoction, this TCM may have as of yet not fully elucidated effects.
Jin Fu Kang
A traditional Chinese herbal medicine derived from the plant Astragalus membranaceus with potential immunopotentiation activity. Jin Fu Kang may stimulate anti-tumor macrophage and natural killer cell activity and may enhance immune recognition of tumor cells by inhibiting the production of T-helper cell type 2 (Th2) cytokines such as interleukin-4 (IL-4) amd interleukin-10 (IL-10).
Jing Si herbal drink
A herbal tea containing eight traditional herbal medicines (THMs), including wormwood, fish needle grass, Ophiopogon japonicas, houttuynia cordata, platycodon, licorice, perilla leaves, and chrysanthemum, with potential anti-inflammatory activity and that can be used to improve fatigue. Upon oral administration, Jin Si herbal tea may improve the feeling of fatigue and weakness in patients with cancer as well as other diseases, such as inflammatory arthritis. Jing Si herbal tea may be able to block the binding of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) to human angiotensin-converting enzyme 2 (ACE2), thereby reducing the penetration ability of of SARS-CoV-2 into human host cells. In addition, Jing Si may affect blood pressure, blood sugar, cholesterol, the human gut microbiota and may reduce inflammatory mediators.
JNK1 inhibitor BMS-986360
An orally bioavailable, second-generation inhibitor of c-Jun N-terminal kinase 1 (JNK-1; JNK1; mitogen-activated protein kinase 8; MAPK8), with potential antineoplastic, anti-inflammatory and anti-fibrotic activities. Upon oral administration, JNK1 inhibitor BMS-986360 selectively targets, binds to and inhibits the activity of JNK1. Inhibition of JNK1-mediated mitogen-activated protein kinase (MAPK)-signaling pathways induces cell cycle arrest and apoptosis, decreases migration and invasion, and inhibits proliferation in JNK1-overexpressing cancer cells. Inhibition of JNK1-mediated pathways may also decrease fibrosis. JNK1, a member of the MAPK family and stress-activated protein, plays a role in the MAPK-mediated signaling pathway. It is often dysregulated in cancer cells and fibrosis.
Jobevne
(Other name for: bevacizumab)
jojoba oil
The oil extracted from the seeds of Simmondsia chinensis. Jojoba oil is used primarily in cosmetics.
Juice Plus
(Other name for: fruit and vegetable extracts)
JUNOVAN
(Other name for: mifamurtide)
Juven
An orally bioavailable nutritional supplement. Juven contains the amino acids glutamine and arginine in addition to beta-hydroxy-beta-methylbutyrate (HMB). This agent may promote muscle protein synthesis and increase muscle mass.
Jylamvo
(Other name for: methotrexate)
Jynneos
(Other name for: MVA-BN smallpox vaccine)